Published in Neuropsychiatr Dis Treat on March 01, 2016
The Role of Norepinephrine and Its α-Adrenergic Receptors in the Pathophysiology and Treatment of Major Depressive Disorder and Schizophrenia: A Systematic Review. Front Psychiatry (2017) 0.75
Effects of α2A Adrenoceptors on Norepinephrine Secretion from the Locus Coeruleus during Chronic Stress-Induced Depression. Front Neurosci (2017) 0.75
Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med (2009) 65.36
The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. PLoS Med (2009) 21.74
Global burden of disease attributable to mental and substance use disorders: findings from the Global Burden of Disease Study 2010. Lancet (2013) 16.76
Physiology and neurobiology of stress and adaptation: central role of the brain. Physiol Rev (2007) 11.15
Stress signalling pathways that impair prefrontal cortex structure and function. Nat Rev Neurosci (2009) 6.22
The catecholamine hypothesis of affective disorders: a review of supporting evidence. Am J Psychiatry (1965) 5.09
Dopamine neuron systems in the brain: an update. Trends Neurosci (2007) 4.44
A double-blind, randomised, placebo controlled study of venlafaxine XL in patients with generalised anxiety disorder in primary care. Br J Gen Pract (2003) 3.30
A double-blind randomized controlled trial of augmentation and switch strategies for refractory social anxiety disorder. Am J Psychiatry (2014) 3.27
Efficacy, safety, and tolerability of venlafaxine extended release and buspirone in outpatients with generalized anxiety disorder. J Clin Psychiatry (1999) 2.44
Role of norepinephrine in the pathophysiology and treatment of posttraumatic stress disorder. Biol Psychiatry (1999) 1.97
Tricyclic antidepressant pharmacology and therapeutic drug interactions updated. Br J Pharmacol (2007) 1.78
Efficacy and safety of pregabalin in the treatment of generalized anxiety disorder: a 6-week, multicenter, randomized, double-blind, placebo-controlled comparison of pregabalin and venlafaxine. J Clin Psychiatry (2006) 1.77
Monoaminergic neurotransmission: the history of the discovery of antidepressants from 1950s until today. Curr Pharm Des (2009) 1.77
Noradrenergic mechanisms in stress and anxiety: II. Clinical studies. Synapse (1996) 1.75
The human raphe nuclei and the serotonergic system. J Chem Neuroanat (2003) 1.74
Once-daily venlafaxine extended release (XR) compared with fluoxetine in outpatients with depression and anxiety. Venlafaxine XR 360 Study Group. J Clin Psychiatry (1999) 1.64
Multi-target strategies for the improved treatment of depressive states: Conceptual foundations and neuronal substrates, drug discovery and therapeutic application. Pharmacol Ther (2006) 1.59
Molecular mechanisms of stress-induced prefrontal cortical impairment: implications for mental illness. Learn Mem (2008) 1.50
The jitteriness syndrome in panic disorder patients treated with antidepressants. J Clin Psychiatry (1988) 1.45
The revised monoamine theory of depression: a modulatory role for monoamines, based on new findings from monoamine depletion experiments in humans. Pharmacopsychiatry (1996) 1.43
A method for controlling for a high placebo response rate in a comparison of venlafaxine XR and diazepam in the short-term treatment of patients with generalised anxiety disorder. Eur Psychiatry (2003) 1.42
Structural insights into adrenergic receptor function and pharmacology. Trends Pharmacol Sci (2011) 1.42
Efficacy, safety, and tolerability of desvenlafaxine 50 mg/day and 100 mg/day in outpatients with major depressive disorder. Curr Med Res Opin (2008) 1.41
Desvenlafaxine succinate: A new serotonin and norepinephrine reuptake inhibitor. J Pharmacol Exp Ther (2006) 1.41
The selective norepinephrine reuptake inhibitor antidepressant reboxetine: pharmacological and clinical profile. CNS Drug Rev (2004) 1.39
Serotonin and drug-induced therapeutic responses in major depression, obsessive-compulsive and panic disorders. Neuropsychopharmacology (1999) 1.30
Noradrenaline systems in the hypothalamus, amygdala and locus coeruleus are involved in the provocation of anxiety: basic studies. Eur J Pharmacol (2000) 1.30
Efficacy of venlafaxine extended-release capsules in nondepressed outpatients with generalized anxiety disorder: A 6-month randomized controlled trial. JAMA (2000) 1.29
Efficacy of extended-release venlafaxine in nondepressed outpatients with generalized anxiety disorder. Am J Psychiatry (2000) 1.29
The brainstem noradrenergic systems in stress, anxiety and depression. J Neuroendocrinol (2010) 1.28
Norepinephrine in depressive reactions. A review. Arch Gen Psychiatry (1965) 1.24
Functional interactions between dopamine, serotonin and norepinephrine neurons: an in-vivo electrophysiological study in rats with monoaminergic lesions. Int J Neuropsychopharmacol (2008) 1.23
Levomilnacipran (F2695), a norepinephrine-preferring SNRI: profile in vitro and in models of depression and anxiety. Neuropharmacology (2013) 1.19
Efficacy and safety of vortioxetine (Lu AA21004), 15 and 20 mg/day: a randomized, double-blind, placebo-controlled, duloxetine-referenced study in the acute treatment of adult patients with major depressive disorder. Int Clin Psychopharmacol (2014) 1.17
Clinical assessment of norepinephrine transporter blockade through biochemical and pharmacological profiles. Circulation (2004) 1.17
Presence of individual (residual) symptoms during depressive episodes and periods of remission: a 3-year prospective study. Psychol Med (2010) 1.16
A randomized controlled trial of venlafaxine extended release in generalized social anxiety disorder. J Clin Psychiatry (2005) 1.16
Collateralized dorsal raphe nucleus projections: a mechanism for the integration of diverse functions during stress. J Chem Neuroanat (2011) 1.14
The role of serendipity in drug discovery. Dialogues Clin Neurosci (2006) 1.11
Treatment of posttraumatic stress disorder with venlafaxine extended release: a 6-month randomized controlled trial. Arch Gen Psychiatry (2006) 1.10
Functional neuroanatomy of the central noradrenergic system. J Psychopharmacol (2013) 1.09
Differential physiological effects of a low dose and high doses of venlafaxine in major depression. Int J Neuropsychopharmacol (2006) 1.08
Efficacy and safety of duloxetine in the treatment of generalized anxiety disorder: a flexible-dose, progressive-titration, placebo-controlled trial. Depress Anxiety (2008) 1.07
Cross-talk between dopaminergic and noradrenergic systems in the rat ventral tegmental area, locus ceruleus, and dorsal hippocampus. Mol Pharmacol (2008) 1.05
Depressive states during Rauwolfia therapy for arterial hypertension; a report of 30 cases. Can Med Assoc J (1956) 1.05
Venlafaxine extended release in posttraumatic stress disorder: a sertraline- and placebo-controlled study. J Clin Psychopharmacol (2006) 1.02
Efficacy of duloxetine for the treatment of generalized anxiety disorder: implications for primary care physicians. Prim Care Companion J Clin Psychiatry (2007) 0.99
Venlafaxine extended release vs placebo and paroxetine in social anxiety disorder. Arch Gen Psychiatry (2005) 0.99
Duloxetine as an SNRI treatment for generalized anxiety disorder: results from a placebo and active-controlled trial. Int Clin Psychopharmacol (2007) 0.96
Noradrenergic neuronal dysregulation in panic disorder: the effects of intravenous yohimbine and clonidine in panic disorder patients. Acta Psychiatr Scand (1992) 0.96
Atomoxetine treatment in adults with attention-deficit/hyperactivity disorder and comorbid social anxiety disorder. Depress Anxiety (2009) 0.96
Invited review: the evolution of antidepressant mechanisms. Fundam Clin Pharmacol (2004) 0.96
Reboxetine, a selective norepinephrine reuptake inhibitor, is an effective and well-tolerated treatment for panic disorder. J Clin Psychiatry (2002) 0.95
The use of venlafaxine in the treatment of major depression and major depression associated with anxiety: a dose-response study. Venlafaxine Investigator Study Group. J Clin Psychopharmacol (1998) 0.93
Selective serotonin reuptake inhibitors (SSRIs): therapeutic drug monitoring and pharmacological interactions. Curr Med Chem (2012) 0.92
Prospect of a dopamine contribution in the next generation of antidepressant drugs: the triple reuptake inhibitors. Curr Drug Targets (2009) 0.91
Efficacy of low and higher dose extended-release venlafaxine in generalized social anxiety disorder: a 6-month randomized controlled trial. Psychopharmacology (Berl) (2004) 0.90
Differential regulation of corticotropin-releasing hormone and vasopressin gene transcription in the hypothalamus by norepinephrine. J Neurosci (1999) 0.90
Duloxetine treatment for relapse prevention in adults with generalized anxiety disorder: a double-blind placebo-controlled trial. Eur Neuropsychopharmacol (2008) 0.90
Efficacy of venlafaxine extended release in patients with major depressive disorder and comorbid generalized anxiety disorder. J Clin Psychiatry (2001) 0.89
Venlafaxine extended-release capsules in panic disorder: flexible-dose, double-blind, placebo-controlled study. Br J Psychiatry (2005) 0.89
Ablation of the central noradrenergic neurons for unraveling their roles in stress and anxiety. Ann N Y Acad Sci (2008) 0.88
Efficacy of pregabalin and venlafaxine-XR in generalized anxiety disorder: results of a double-blind, placebo-controlled 8-week trial. Int Clin Psychopharmacol (2009) 0.88
Switching to duloxetine in selective serotonin reuptake inhibitor non- and partial-responders: effects on painful physical symptoms of depression. J Psychiatr Res (2008) 0.88
A randomized controlled trial of venlafaxine ER and paroxetine in the treatment of outpatients with panic disorder. Psychopharmacology (Berl) (2007) 0.88
Time to relapse after 6 and 12 months' treatment of generalized anxiety disorder with venlafaxine extended release. Arch Gen Psychiatry (2010) 0.88
Presynaptic alpha-receptor subsensitivity after long-term antidepressant treatment. Science (1978) 0.87
A double-blind study of the efficacy of venlafaxine extended-release, paroxetine, and placebo in the treatment of panic disorder. Depress Anxiety (2007) 0.87
A non-inferiority comparison of duloxetine and venlafaxine in the treatment of adult patients with generalized anxiety disorder. J Psychopharmacol (2008) 0.87
A double-blind, placebo-controlled, parallel-group, flexible-dose study of venlafaxine extended release capsules in adult outpatients with panic disorder. J Clin Psychiatry (2009) 0.86
A study of the effects of LY2216684, a selective norepinephrine reuptake inhibitor, in the treatment of major depression. J Psychiatr Res (2009) 0.86
Randomized placebo-controlled trial of escitalopram and venlafaxine XR in the treatment of generalized anxiety disorder. Depress Anxiety (2008) 0.86
Efficacy of once-daily venlafaxine extended release (XR) for symptoms of anxiety in depressed outpatients. J Affect Disord (1998) 0.86
Influence of ligand binding kinetics on functional inhibition of human recombinant serotonin and norepinephrine transporters. J Pharmacol Toxicol Methods (2009) 0.85
A randomized controlled trial of atomoxetine in generalized social anxiety disorder. J Clin Psychopharmacol (2009) 0.85
Switching to duloxetine from selective serotonin reuptake inhibitor antidepressants: a multicenter trial comparing 2 switching techniques. J Clin Psychiatry (2008) 0.84
Duloxetine versus placebo in the treatment of patients with generalized anxiety disorder in China. Chin Med J (Engl) (2011) 0.84
Efficacy of venlafaxine in depressive illness in general practice. Acta Psychiatr Scand (1997) 0.83
A double-blind, placebo-controlled study of a flexible dose of venlafaxine ER in adult outpatients with generalized social anxiety disorder. J Clin Psychopharmacol (2004) 0.83
Venlafaxine for panic disorder: results from a double-blind, placebo-controlled study. Psychopharmacol Bull (1996) 0.83
A review of the clinical efficacy, safety and tolerability of the antidepressants vilazodone, levomilnacipran and vortioxetine. Expert Opin Pharmacother (2014) 0.83
Improvement of psychic and somatic symptoms in adult patients with generalized anxiety disorder: examination from a duloxetine, venlafaxine extended-release and placebo-controlled trial. Psychol Med (2008) 0.82
Neurotransmitter targeting in the treatment of depression. J Clin Psychiatry (2013) 0.82
Pattern of symptom improvement following treatment with venlafaxine XR in patients with generalized anxiety disorder. J Clin Psychiatry (2001) 0.82
A double-blind crossover comparison of clomipramine and desipramine in the treatment of panic disorder. Eur Neuropsychopharmacol (1999) 0.81
Remission rates with venlafaxine extended release in Greek outpatients with generalized anxiety disorder. A double-blind, randomized, placebo controlled study. Int Clin Psychopharmacol (2004) 0.81
Venlafaxine extended release in the short-term treatment of depressed and anxious primary care patients with multisomatoform disorder. J Clin Psychiatry (2006) 0.80
Electrophysiological characterization of adrenoceptors in the rat dorsal hippocampus. II. Receptors mediating the effect of synaptically released norepinephrine. Brain Res (1988) 0.80
Response of the norepinephrine system to antidepressant drugs. CNS Spectr (2001) 0.80
A randomised, double-blind, placebo-controlled, duloxetine-referenced study of the efficacy and tolerability of vortioxetine in the acute treatment of adults with generalised anxiety disorder. Int J Clin Pract (2014) 0.80
Efficacy of Venlafaxine ER in patients with social anxiety disorder: a double-blind, placebo-controlled, parallel-group comparison with paroxetine. Hum Psychopharmacol (2004) 0.79
The noradrenergic symptom cluster: clinical expression and neuropharmacology. Neuropsychiatr Dis Treat (2011) 0.79
What are the clinical implications of new onset or worsening anxiety during the first two weeks of SSRI treatment for depression? Depress Anxiety (2011) 0.79
Differential inhibitory effects of drugs acting at the noradrenaline and 5-hydroxytryptamine transporters in rat and human neocortical synaptosomes. Br J Pharmacol (2009) 0.78
Preliminary report: placebo-controlled, double-blind study of the clinical and metabolic effects of desipramine in panic disorder. Psychopharmacol Bull (1993) 0.78
Social adjustment in generalised anxiety disorder: a long-term placebo-controlled study of venlafaxine extended release. Eur Psychiatry (2004) 0.77
Pooled analysis of venlafaxine XR efficacy on somatic and psychic symptoms of anxiety in patients with generalized anxiety disorder. Depress Anxiety (2004) 0.77
Attributes of response in depressed patients switched to treatment with duloxetine. Int J Clin Pract (2010) 0.77
Relapse prevention of panic disorder in adult outpatient responders to treatment with venlafaxine extended release. J Clin Psychiatry (2007) 0.76